Hier finden Sie grundlegende Angaben zu klinischen Studien des Comprehensice Cancer Centers Mainfranken (CCC MF)
Filter aktiv
Seite 7 - Studien 61 bis 70 von insgesamt 347
- Rekrutierung läuftCAELUM Cardiac Amyloid Reaching for Extended Survival A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Stage IIIb AL Amyloidosis
- Rekrutierung läuftA Phase 3 Randomized, Double-blind, Placebo-controlled, Study of Bleximenib, Venetoclax and Azacitidine for the Treatment of Participants with Newly Diagnosed Acute Myeloid Leukemia Harboring KMT2ARearrangements or NPM1Mutations who are Ineligible for Intensive Chemotherapy
- Rekrutierung läuftCAPTOR-BC: Comprehensive analysis of spatial, temporal and molecular patterns of Ribociclib efficacy and resistance in advanced breast cancer patients
- Rekrutierung läuft
Long Term Follow-Up of Patients Exposed to Lentiviral-Based CD19 directed CART Cell Therapy (PAVO)
- Rekrutierung läuftChirurgische Therapie für das Adenokarzinom des gastroösophagealen Überganges (AEG Typ II): Transthorakale Ösophagektomie vs. Transhiatal erweiterte Gastrektomie.DRKS00016923
- Rekrutierung läuftCARMAN: Early treatment intensification in patients with high risk Mantle Cell Lymphoma using CAR-T-cell treatment after an abbreviated induction with Rituximab and Ibrutinib and 6 months Ibrutinib maintenance following CAR-T-cell treatment (Arm A) as compared to standard of care induction and maintenance (Arm B)
- Rekrutierung läuftA non-interventional study for Kisqali (Ribociclib) in combination with an aromatase inhibitor in patients with HR+/HER2- stage II and III early breast cancer to evaluatereal-world effectiveness, safety profile, patient compliance and quality of life (CAROLEEN).Molekulare Marker
- Rekrutierung läuftCART-Zell-Funktion an Glioblastom Primärzelllinien
- Rekrutierung läuftA Phase 3 Randomized Study Comparing Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Ciltacabtagene Autoleucel versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in Participants with Newly Diagnosed Multiple Myeloma who are Transplant Eligible
- Rekrutierung läuftA Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus
Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in
Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small
Lymphocytic LymphomaMolekulare Marker